Marianne Davies, RN, MSN, ACNP, AOCN, Smilow Cancer Hospital, Yale School of Nursing, discusses how to determine which patients are eligible for immunotherapy.
Marianne Davies, RN, MSN, ACNP, AOCN, Smilow Cancer Hospital, Yale School of Nursing, discusses how to determine which patients are eligible for immunotherapy.
Davies explains that immunotherapy targets the patients’ immune system to prime it to fight the cancer instead of attacking the tumor itself. However, the newly primed T cells can also attack healthy cells.
When screening patients for these therapies, it’s important to see if they already have an over-reactive immune system, Davies says. An immunotherapy in these patients can lead to severe adverse events or even death.
Davies says it is also unknown how immunotherapies affect patients who are on steroids. Patients that have a high tumor burden are also not ideal candidates for immunotherapy. These patients need a more rapid response, Davies says.
<<<
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.